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http://dxDespite advances in microbial prevention and elimination, the frequency of endocardial infection is still
increasing and it remains to be a serious condition. The strategies and aggressiveness of medical and surgical
algorithms for managing these patients are evolving and having a significant effect on morbidity and mortality.
This review addresses the current understanding of the processes by which the most common and most threat-
ening complications occur, and the current management strategies that cardiologists and cardiac surgeons should
be aware of when treating these seriously ill patients. (J Thorac Cardiovasc Surg 2014;147:1133-41)Despitemajor advances in diagnosticmodalities and antimi-
crobial therapies, infective endocarditis (IE) remains an
extremely ominous infection, with a 1-year mortality rate
of up to 40%.1,2 Management of these critically ill
patients requires an understanding of the disease process
in its various microbial, hemodymanic, embolic, and
immunologic forms. At the time of diagnosis, patients
have often progressed to complications through 1 aspect of
the disease. An appreciation of the spectrum of the disease
processes is crucial for providing a timely and effective
intervention. In this article, the processes by which the
most common and most threatening complications occur,
as well as what every physician ought to know when
treating these seriously ill patients are discussed.OVERVIEW OF COMPLICATIONS
After bacteria seed the endocardium, erosions into
various cardiac structures take place though an interplay
of direct bacterial invasion, enhanced inflammatory
response, and liquifactive enzyme release within cardiac
tissues. This is particularly pronounced in IE caused by
Staphylococcus aureus, especially in the aortic valve
position. This is probably due to the less annular fibrous tis-
sue support in the aortic position compared with the mitral
position. Unfortunately, IE tends to occur more frequently
in the aortic valve than any other valve, and the frequency
of S aureus as the cause of IE has increased dramatically
over the past 2 decades, from 2% in 1990 to 25% in 2009.3
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The Journal of Thoracic and Carregurgitant lesion or shunt creation, can complicate IE.
Sudden regurgitation usually occurs as a result of chordal
rupture in native valve endocarditis (NVE), a valve leaflet
perforation in NVE or in bioprosthetic valve IE, or valve
dehiscence in prosthetic valve endocarditis (PVE). In
NVE and PVE, CHF is the complication with the greatest
independent impact on prognosis whether medically or sur-
gically treated.4,5 Early studies comparing antimicrobial
therapy with surgery in patients with IE complicated by
CHF demonstrated a clear superiority with surgery (23%
vs 71% mortality rates).6-8 Much less commonly, heart
failure can be obstructive in nature when large vegetation
obstructs a heart chamber outflow.
A similar pathophysiology also leads to paraannular
extension (PAE) of the infection. Given the similar
pathophysiology, PAE is also more common with necro-
tizing organisms, and in the aortic position. In addition,
PAE is one of the most frequent complications of IE,
occurring in up to 100% of infected prosthetic valves and
40% of infected native valves.9 The infectious process
around the valve weakens the annulus, and eventually leads
to tissue destruction, valve dehiscence, abscess formation,
and sometimes fistulization. This is associated with an
increased occurrence of CHF and a higher mortality rate.
A PAE-related fistula has been shown to lead to up to
40% mortality.10,11
In addition to the local destruction that complicates IE,
systemic embolization is the most common complication.
Emboli usually consist of vegetations or friable necrotic
and often infected tissues. Unlike local effects, this is
more common in the mitral valve position. Although the
embolic risk is high (embolic events occur in up to 50%
of patients), this risk declines dramatically with initiation
of antibiotic treatment, and even more after 2 weeks of
effective continuation.3,12-14 The rate of systemic
embolization is significantly higher in patients who have
had a previous embolic event, those in the first 2 weeks of
antibiotic therapy, those with left-sided IE especially in
the mitral position, those with mobile vegetation that is
large (10-15 mm) or increasing in size despite antibiotic
therapy, and those patients infected with certain pathogensdiovascular Surgery c Volume 147, Number 4 1133
Expert Review Bedeir et al11Abbreviations and Acronyms
ACC ¼ American College of Cardiology
CHF ¼ congestive heart failure
CT ¼ computed tomography
ESC ¼ European Society of Cardiology
GFP ¼ glutaraldehyde-fixed pericardial
IE ¼ infective endocarditis
MIC ¼ minimum inhibitory concentration
MRI ¼ magnetic resonance imaging
NVE ¼ native valve endocarditis
PAE ¼ paraannular extension
PVE ¼ prosthetic valve endocarditis
TEE ¼ transesophageal echocardiography
TTE ¼ transthoracic echocardiography34 Th(S aureus, fungi, enterococci, and HACEK).3,12,15 No
vascular bed is immune, but 65% of these pathogens
usually affect the brain, 90% in the middle cerebral artery
territory. Renal and splenic vascular beds are also
commonly involved.16 When a septic embolus reaches its
target, it ends up causing an infarction, an abscess usually
with S aureus, or rarely a mycotic aneurysm when the intra-
mural vasa vasora are involved. This is usually followed by
wall attenuation and progressive aneurysmal dilatation of
the affected vessel.
Less virulent organisms usually have a less pronounced
local effect. An indolent subacute course triggers an anti-
body response that puts the patient at risk of immune com-
plex glomerulonephritis. Acute renal failure complicates up
to 30% of patients with IE and is associated with a poor
prognosis. This is especially true when it is compounded
by septic renal embolism, prerenal failure caused by CHF,
and the nephrotoxic effects of gentamicin and vancomycin,
commonly used in high doses for treating these patients.17
MAKING THE DIAGNOSIS
An accurate diagnosis is crucial. Missing a diagnosis
likely leads to a poor outcome or death, and overdiagnosing
patients leads to exposure to high doses of potentially toxic
antimicrobials that are unnecessary. Several defining
criteria have been proposed including those by Pelletier
and Petersdorf18 and Von Reyn and colleagues19; however,
the more recent Duke criteria and their revisions in 2000
seem to be the most widely used.20,21 Based on the latter,
a diagnosis is made if any of the following is present: (1)
pathologically tested tissue; (2) 2 major criteria; (3)
1 major plus 3 minor criteria; or (4) 5 minor criteria
(Table 1). A high pretest probability justifies commencing
treatment even if the diagnosis is not definite according to
the criteria.e Journal of Thoracic and Cardiovascular SurCornerstone major criteria include blood cultures and
echocardiographic findings. However, an accurate diag-
nosis is not always straightforward, given that 25% to
30% of patients in this era present with no previously
known cardiac structural abnormality.22 This is in part
due to the more acute rather than subacute disease process
taking place with the increased prevalence of S aureus as
a causative agent. An accurate diagnosis has been made
even more difficult by increasing rates of culture-negative
IE. In the United States, 79% of cases with culture-
negative IE were found to be due to early administration
of antimicrobials or faulty culturing technique, empha-
sizing their relative importance and how seemingly trivial
details may alter or complicate the diagnosis.23
Echocardiography should be done as soon as IE is
suspected. The role of echocardiography goes beyond the
diagnosis, and repeat echocardiography is recommended
on clinical deterioration or when complications are sus-
pected. Echocardiography guides the decision on whether
to operate and when, as discussed later. However, the role
of transthoracic echocardiography (TTE) in the assessment
of left-sided IE is controversial, because of its significantly
lower negative predictive values compared to transesopha-
geal echocardiography (TEE).24,25 Although TEE has a
near 100% negative predictive value with NVE, it is
operator dependent and is far less sensitive for PVE and
abscesses of the mitral valve associated with posterior
annular calcification.3,26 In these situations, repeat TEE
as well as a combination of TTE and TEE might
mitigate the limitations caused by acoustic shadowing.
Unfortunately, 15% of patients with proven IE were
reported to have no echocardiographic findings.27
STARTING MANAGEMENT
Managing a patient with IE aims at 2 goals: eradica-
tion of infection and restoration of cardiac structures.
Eradicating infection, whether medically or surgically,
should abort the disease process, and thus prevent
further local, hemodynamic, immunologic, or embolic
complications. Structural restoration is primarily surgi-
cal and is aimed at repairing the damaged tissue in
which healing would not be sufficient, and would
otherwise have short-term or long-term hemodynamic
implications.
Once the diagnosis of IE is suspected, at least 3 sets of
blood culture samples should be drawn from different sites
and at 30-minute intervals.28,29 This should be followed
immediately by initiation of intravenous empirical
antibiotic therapy as shown in Table 2. With no justification
for delay, this empirical therapy should be qualitatively
bactericidal and quantitatively in high doses for up to 6
weeks. Selecting the best antibiotic for a particular patient
should be guided by the presence or absence of previous
antibiotic use, whether this is a suspected case of NVE,gery c April 2014
TABLE 1. Major and minor revised Duke criteria
Major Minor
Persistent positive blood culture with
typical infective endocarditis
microorganism
Predisposing factor: known
cardiac lesion, recreational
drug injection
Evidence of endocardial involvement
with echocardiogram
Fever>38C
Evidence of embolism
Immunologic problems
Positive blood culture (that does
not meet a major criterion)
Bedeir et al Expert Reviewearly PVE or late PVE, and by consultation with the
microbiological team regarding epidemiologic clues for
pathogen trends and antibiotic resistance at that specific
area or facility. A list of generally encountered epidemio-
logic clues that might guide antibiotic selection has been
published previously.30
In general, the nature and pathogenesis of early PVE is
different from other forms of IE. NVE and late PVE usually
occur with distant blood stream pathogen access, which
eventually leads to pathogen adherence at a point in the
heart that has been previously predisposed, whether by dis-
ease causing a jet and Venturi effect on the low-pressure
side or by an implanted prosthesis. On the other hand, early
PVE is mostly caused by microbes that can adhere to the
annulus-ring interface and to the perivalvular suture
pathways when they are coated with fibronectin and
fibrinogen before endothelialization takes place. Inocula-
tion typically takes place within the first 60 days after
surgery and is usually nosocomial. After this period, and
up to 12 months, there is a transition in pathogenesis and
causative organisms that ends with complete endothelia-
lization. The mechanism, the microbiology, and the
incidence of PVE beyond 12 months are similar to NVE.
Both the American Heart Association (AHA)/American
College of Cardiology (ACC) and the European Society of
Cardiology (ESC) guidelines regard gentamicin as an optional
addition to initial combination therapy, because of its
presumed synergistic effect with cell-wall inhibitors.
The ESC guidelines, however, recommend it for PVE.3,28
A valid argument against gentamicin has been proposed,
given its proven renal toxicity against the background
of doubtful benefit.31,32 These studies recommended theTABLE 2. Empirical antimicrobial therapy with early PVE, late PVE,
and NVE
Early PVE (<12 months
after surgery)
NVE and late PVE (12 months
after surgery)
Vancomycin plus
rifampin
( gentamicin)
Combination penicillins (ampicillin-sulbactam
and amoxicillin-clavulanate) ( gentamicin)
If intolerant to penicillins: vancomycin plus
ciprofloxacin ( gentamicin)
The Journal of Thoracic and Caruse of daptomycin as a noninferior option for proven
staphylococcal infection rather than standard therapy
including gentamicin. However, the impact of gentamicin
on creatinine clearance did not seem to lead to dialysis
or otherwise adversely affect the patients’ course in these
studies.
With the exception of staphylococcal infections, fever
should resolve within a few days after starting therapy,
and all patients should have surveillance blood cultures af-
ter 3 to 4 days of intravenous drug therapy. In a significant
number of patients, cultures are negative, and this should
never rule out IE. As mentioned earlier, previous antibiotic
use is a common reason why cultures are not positive.
Also slow-growing or atypical organisms (Q-fever and
Bartonella) and fungal infection might be present.30,33MODIFYING THERAPY
In most true cases of IE, blood cultures are positive and
therapy should be modified accordingly. Lists of different
drug regimens, doses, combinations, and durations of
therapy for cultured organisms have been published
previously.3,30 Medical regimens should not be modified
based only on qualitative microbial sensitivity. Minimum
inhibitory concentrations (MIC) of specific drugs for
specific pathogens should be followed. For example, S
aureus exists in strains that are vancomycin intolerant and
stop growing in the presence of the drug rather than die.
These strains resurge after the treatment stops. Moreover,
the high trough levels of vancomycin that are necessary
for this growth inhibition are also enough to cripple the
patient’’s renal function. In this situation, the MIC
should guide the substitution of vancomycin with less
nephrotoxic alternatives such as daptomycin or
teicoplanin.32,34
Generally, antimicrobial combinations are preferred over
monotherapy. This increases efficacy, reduces required drug
doses and thus adverse effects, reduces the emergence of
resistant strains, and shortens the duration of therapy.
Aminoglycosides synergize with b-lactams and glycopep-
tides, and slow-growing or dormant pathogens residing
within vegetation or biofilms justify the need for rifampicin
for prolonged duration.3CLOSE MONITORING
While antibiotic therapy is continued, close monitoring
for treatment effectiveness and disease progression is key
to the success of treatment. Fever and various indicators of
ongoing inflammation have to be followed attentively,
renal function and other side effects of the drugs should
be anticipated, and complications of disease progression
should be vigorously dealt with. The importance of close
monitoring should be emphasized to allow for effective
modifications of therapy and timely surgical intervention.diovascular Surgery c Volume 147, Number 4 1135
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most ominous complication of IE, and must treated aggres-
sively. It is an AHA/ACC and ESC class I indication for sur-
gery in patients with IE.3,28 The status of the infection should
be completely disregarded when there is any evidence of
hemodynamic instability or pulmonary edema, and
surgical delay beyond 24 hours in not acceptable. In
hemodynamically stable patients, urgent surgery should be
performed when there are echocardiographic features of
poor hemodynamic tolerance.3 With mitral valve IE, evi-
dence of severe mitral regurgitation, including a rapidly
decelerating late systolic transmitral signal (V-wave cut-
off Doppler sign) as a result of markedly increased left atrial
pressure or a finding of moderate to severe pulmonary hy-
pertension, are signs of impending CHF. With aortic valve
IE, premature closure of the mitral valve is an early sign
of an overfilling left ventricle. These features should be spe-
cifically looked for, and emphasize the importance of repeat
echocardiography when monitoring patients with known
IE. In patients with mild CHF who are responding favorably
to medical therapy, afterload reduction may be adopted with
strict clinical and echocardiographic monitoring, while
having the patient and the facility ready for urgent surgery.
A ruptured sinus of Valsalva into a heart chamber or into
the pericardium is a complication that should be treated
with similar urgency with a delay in surgery of no more
than 24 hours. Otherwise, the indications for surgery are
less clear and the decision and timing of surgical interven-
tion is a difficult balance between the need to optimize the
patient’s medical condition and the fact that these patients
are often extremely unwell and can deteriorate irreversibly
at any moment. Generally, fungal, staphylococcal, or
gram-negative endocarditis is almost always a surgical
disease. PVE and device-related (pacemaker or implantable
cardioverter defibrillator) endocarditis, a steeply increasing
type of IE, should have a much lower threshold for surgery
compared with NVE. On the other hand, right-sided
endocarditis should have a higher threshold for surgery,
and should primarily be considered a medical disease
with some exceptions. In any case, consultation between
the cardiologist and the cardiac surgeon should take place,
and the patient with PVE should be taken off coumadin and
aspirin, with heparin infusion replacement.
When fever and inflammatory mediators are persistently
high despite adequate doses of appropriate antibiotic treat-
ment, PAE has to be suspected. With any degree of unex-
plained heart block noted, abscess formation is likely. In
both situations, TEE should be ordered immediately. An
annular or aortic abscess, a new heart block, or valve dehis-
cence are considered class I indications for surgery.11,28
However, some investigators argue that nonresolving
fever and increased inflammatory mediators despite 1
week of antibiotic therapy, together with positive
surveillance blood cultures, should suffice for making the1136 The Journal of Thoracic and Cardiovascular Surdecision on surgery.35 In the case of shunt caused by IE
and its high mortality rate, surgical intervention should be
always performed, even in the absence of any evidence of
heart failure.11 In a few selected cases, medical therapy
alone would be accepted in the context of confirmation of
PAE. This can be the case when the isolated organism is
sensitive, there is no evidence of valve destruction or heart
block, and when abscesses are less than 1 cm in size.
Otherwise, surgery should not be delayed.35
Because of the relatively high rate of embolism in the first
2 weeks after diagnosis, patients at high risk of emboliza-
tion should be identified, given that early surgery would
potentially be more beneficial in these patients. As
described earlier, with left-sided and especially mitral valve
IE (anterior leaflet in particular), timely surgery might save
patients who have had previous embolism and infections
caused by certain organisms from disabling embolic events.
The decision of surgery based on vegetation criteria alone is
still controversial. The 2006 ACC/AHA guidelines recom-
mend surgery as a class IIa indication only for those with
recurrent emboli and persistent vegetation after antibiotic
therapy.33 The 2009 ESC guidelines recommend urgent
surgery as a class IIb indication for vegetation greater
than 15 mm in diameter.3 A recent randomized controlled
study has clarified this gray zone regarding the impact of
early surgery on embolic events. Kang and colleagues36
randomized patients with left-sided IE and vegetation
greater than 10 mm to either conventional early antibiotic
treatment or surgery within 48 hours of randomization.
Early surgery showed a significantly reduced composite
end point of death from any cause and embolic events by
effectively decreasing the risk of systemic embolism.
For patients who have already had a neurologic event,
surgery is not contraindicated after transient ischemic
attacks or ischemic (nonhemorrhagic) strokes. Although
some controversy exists around the exact time frame for
surgery after the event, in consensus, surgery should not
be delayed after a nonhemorrhagic stroke in the presence
of heart failure, PAE, ongoing sepsis, or persistent high
embolic risk.37 A computed tomography (CT) scan should
be done on the brain before surgery to exclude the possibil-
ity of a hemorrhagic stroke. In the extremely unfortunate
situation with an emergency indication of surgery in the
setting of a hemorrhagic stroke, limited data are available
and poor outcomes are expected with either conservative
or operative management. In this situation, a wise decision
should be made weighing the benefits and risks depending
on the extent of hemorrhage, duration since onset, and
association with neurologic deficit on the one hand, and
the degree of hemodynamic compromise, the response to
antimicrobial therapy, the anticipated complexity of
surgery, and thus the anticipated cardiopulmonary bypass
time on the other hand. On the contrary, recurrent pulmo-
nary embolization in right-sided IE is not considered angery c April 2014
TABLE 3. Potential complications of infective endocarditis and the recommended approaches for management
Complication Management
Congestive heart failure (clinical or echocardiographic) Surgery within 24 h, regardless of the status of the infection
Paraannular extension Ruptured sinus of Valsalva
Abscess In the absence of congestive heart failure, stabilizing the patient and controlling the infectious
process medically should be attempted first. Surgery will be required eventually for
structural restoration
Conduction block
Prosthetic valve dehiscence
Embolization Cerebral Hemorrhagic stroke should be excluded first.
Ischemic stroke does not preclude emergency
or urgent surgery for hemodynamic and
infectious complications of infective
endocarditis
Result from a recent randomized controlled trial
show superior outcomes with surgery within
48 h for left-sided infective endocarditis with
vegetation>10 mm
Splenic Differentiation between infarcts and abscesses
is crucial. Infarcts should be conservatively
managed whereas abscesses will fail
conservative trials and warrant splenectomy
after stabilizing the patient. The splenic
abscess should be addressed before any
prosthetic valves, patches, or grafts are
placed in the heart
Renal Multifaceted medical management should be
initiated to address renal ischemia, immune
glomerulonephritis, as well as modification
of antimicrobial therapy type or dose
Right-sided (pulmonary) In the abscess of lung abscess, conservative management is recommended
Bedeir et al Expert Reviewindication for surgery in the absence of pulmonary
abscesses.38
Splenic infarctions are common (44%) and usually
improve with medical therapy alone, but splenic
abscesses, which are not easily differentiated from
infarcts are not expected to improve with medical
therapy. Abdominal CT scan and magnetic resonance
imaging (MRI) should be correlated with a high index
of suspicion with poor clinical response to ongoing
antibiotic therapy, and once a splenic abscess is diag-
nosed, a splenectomy is warranted as soon as the
patient’s clinical status permits.13 The management is
highly individualized, however, it is crucial to remove
the spleen, whether by open or laparoscopic surgery,
because it is a source of ongoing sepsis, before operating
on the heart; otherwise, prosthetic grafts or valves will
likely get infected.39 If the patient’s clinical status neces-
sitates urgent or emergency cardiac restoration surgery,
concomitant splenectomy should be done if the patient
is expected to tolerate such a procedure, otherwise imme-
diate percutaneous aspiration of splenic abscesses is
reasonable, followed by immediate cardiac surgery.13
The situation with poor clinical and inflammatory
improvement with adequate and appropriate antibiotic
therapy can be less straightforward. When abdominal CT
or MRI scans are negative for abscesses, an alternative
focus should be searched for. This can be difficult, and
entails a detailed history for implants, orthopedic or anyThe Journal of Thoracic and Carother hardware, as well as a thorough physical examination
including a dental examination. When no septic focus is
found, we believe that a positron emission tomography/
CT scan is a reasonable modality to accurately identify a
hypermetabolic infected site.40-42 As with splenic
abscesses, the septic focus should be dealt with before or
at the same time as implanting any prosthetic valves,
patches, or grafts in the heart (Table 3).
OPERATING
Approximately half of patients with IE require surgery.
Surgery for IE revolves around eradicating infection and de-
briding all necrotic tissue, with subsequent reconstruction
of the cardiac chambers and valves. The reconstructive ma-
terial should ideally provide durability and a low reinfection
rate. Achieving these goals can be technically challenging
at times. Repairs generally tend to be more complex and
technically difficult when the infection spreads beyond
the annulus. To a great extent, this is proportional to the
virulence of the organism. Every effort should be made to
avoid implanting a prosthesis. In some cases, implanting a
prosthesis becomes inevitable because of extensive tissue
destruction, and bioprostheses are always preferred over
mechanical valves, and homografts and stentless valves
may provide valvular support when the perivalvular tissue
is extensively destroyed.43,44 The use of antibiotic-
impregnated fibrin glue has been proposed to seal prosthetic
valve sewing cuffs as well as abscess cavities.45,46 This isdiovascular Surgery c Volume 147, Number 4 1137
FIGURE 1. Less extensive aorto-mitral curtain involvement can allow for primary or pericardial patch repair. A-C, Steps as labeled in the diagram.
(Reprinted with permission from Ramlawi B, Reardon MJ. Endocarditis with involvement of the aorto-mitral curtain. Op Tech Thorac Cardiovasc Surg.
2011;16:242-9.)
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infection rate using antibiotic-impregnated fibrin glue
compared with antibiotic alone, fibrin glue alone, or sa-
line.47 However, comparative studies in humans are lacking.
Especially with mitral valve IE, every attempt should be
made to repair. Reparability ranges between 34% and 80%
in different reports.48-51 The feasibility of repair seems
be highest with either early active disease or with
healed disease as an elective procedure. The former
emphasizes the importance of prompt surgery with the
earliest echocardiographic signs of decompensation with1138 The Journal of Thoracic and Cardiovascular Surregurgitant lesions. Even with more advanced active IE
with extensive leaflet destruction, repair should be
attempted first.
Annuloplasty, as with all mitral regurgitation repairs, is
recommended. With IE, the outcomes after autologous
glutaraldehyde-fixed pericardial (GFP) annuloplasty are
effective and durable.52 Leaflet repair is always preferred
over valve replacement, and excellent results have been re-
ported. Zegdi and colleagues53 reported a 10-year freedom
from mitral reoperation of 91% using the Carpentier
techniques in mitral valve endocarditis repair. Preservationgery c April 2014
FIGURE2. Withmoreextensive aorto-mitral curtain involvement, adequate eradicationof infectionmight require the removal of the entireaortic root,with recon-
struction using an aortic root allograft with retained anterior mitral leaflet together with coronary reimplantation. A-D, Steps as labeled in the diagram. (Reprinted
with permission from Ramlawi B, Reardon MJ. Endocarditis with involvement of the aorto-mitral curtain. Op Tech Thorac Cardiovasc Surg. 2011;16:242-9.)
Bedeir et al Expert Reviewof the left ventricular structure as well as the subvalvular
apparatus might partly explain why repair can be better
tolerated than replacement in the setting of CHF. OtherThe Journal of Thoracic and Carstudies have also reported favorable results and lower rates
of reinfection with repair.48,50,54,55 With extensive bileaflet
destruction, a GFP fashioned leaflet can be attempted,diovascular Surgery c Volume 147, Number 4 1139
Expert Review Bedeir et alhowever, success rates and variations in durability are
significant for different institutions and surgeons with
mitral valve expertise. Total mitral valve homografts
should be the last resort, given their technical difficulty
as well as their less than optimal durability and high
rates of reoperation.56,57
In contrast to the mitral position, aortic valve IE that
requires surgery usually requires valve replacement.
Homografts seem to be the best option, given the increased
tendency of aortic valve infections to extend beyond the
annulus. This is also the case with PVE, for which
significant tissue debridement is necessary.58,59
Infections extending into the left fibrous trigone or
aorto-mitral curtain can pose a challenge. Less extensive
lesions can be repaired primarily or using a GFP patch,
however more extensive lesions require extensive debride-
ment and total en-bloc replacement using an aorto-mitral
homograft (Figures 1 and 2).60 The Ross procedure is an
option, although not many surgeons would achieve
acceptable results.
Right-sided IE less commonly requires surgery.
Tricuspid valve excision has been advocated in intravenous
drug users with a high incidence of recurrence of tricuspid
valve infection, but this was followed by unacceptable
severe right-sided heart failure, and thus, this approach is
no longer recommended. Bioprostheses seem to offer
better results at the cost of higher chances of reinfection,
especially with continued drug abuse.61
The duration of therapy should be based on the first day
of effective antibiotic therapy, not on the day of surgery, if
surgery took place. A new full antimicrobial course is only
started after surgery if valve cultures are positive, and in
this case, the choice of antibiotic should be modified
accordingly.3 With PVE and device-related IE, prolonged
antibiotic therapy is recommended for at least 6 weeks,
and a new device should not be implanted except when
complete microbiological eradication is achieved.3
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